Editas Medicine, Inc., Announces Pricing of $50 Million Offering of Common Stock
December 06 2017 - 7:00AM
Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing
company, today announced the pricing of an underwritten offering of
1,970,000 shares of its common stock. The gross proceeds to Editas
Medicine from this offering are expected to be approximately $50
million, before deducting estimated offering expenses. Editas
Medicine has granted the underwriter a 30-day option to purchase up
to an additional 295,500 shares of common stock on the same terms
and conditions. All of the shares in the offering are to be sold by
Editas Medicine.
Morgan Stanley is acting as sole book running manager for the
offering.
The securities described above are being offered pursuant to a
shelf registration statement (File No. 333-216444), which was
declared effective by the Securities and Exchange Commission (SEC)
on March 15, 2017. The offering is being made only by means of a
prospectus supplement and the accompanying prospectus. A final
prospectus supplement relating to the offering will be filed with
the SEC and will be available at www.sec.gov. When available,
copies of the final prospectus supplement and the accompanying
prospectus may be obtained by contacting Morgan Stanley & Co.
LLC, Attention: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, New York 10014.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to
treating patients with genetically-defined diseases by correcting
their disease-causing genes. The Company was founded by world
leaders in genome editing, and its mission is to translate the
promise of genome editing science into a broad class of
transformative genomic medicines to benefit the greatest number of
patients.
Forward-Looking Statements
This press release contains forward-looking statements and
information within the meaning of The Private Securities Litigation
Reform Act of 1995. The words “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “target,” “should,” “would,”
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements as a result of various factors,
including: the uncertainties related to whether or not the Company
will be able to raise capital through the sale of shares of common
stock, the final terms of the proposed offering, market and other
conditions, the satisfaction of customary closing conditions
related to the proposed public offering and the impact of general
economic, industry or political conditions in the United States or
internationally; uncertainties inherent in the initiation of
preclinical studies and clinical trials and clinical development of
the Company’s product candidates; availability and timing of
results from preclinical studies and clinical trials; whether
interim results from a clinical trial will be predictive of the
final results of the trial or the results of future trials;
expectations for regulatory approvals to conduct trials or to
market products and availability of funding sufficient for the
Company’s foreseeable and unforeseeable operating expenses and
capital expenditure requirements. These and other risks are
described in greater detail under the caption “Risk Factors”
included in Editas’ Quarterly Report on Form 10-Q for the quarter
ended September 30, 2017 filed with the SEC on November 8, 2017,
the Company’s preliminary prospectus supplement filed with the SEC
on December 5, 2017, and other filings the Company may make with
the SEC in the future. Any forward-looking statements contained in
this press release speak only as of the date hereof, and the
Company expressly disclaims any obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
ContactsMedia:Cristi
Barnett(617) 401-0113cristi.barnett@editasmed.com
Investors:Mark Mullikin(617)
401-9083mark.mullikin@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Apr 2023 to Apr 2024